Biogen (BIIB) PT Lowered to $213 at RBC Capital

April 7, 2026 9:02 AM

RBC Capital analyst Brian Abrahams lowered the price target on Biogen (NASDAQ: BIIB) to $213.00 (from $233.00) while maintaining a rating.

No results found